Abstract. MicroRNAs are proposed to serve vital functions in the regulation of tumor progression and invasion. However, the expression levels of miR-203 in non-small cell lung cancer (NSCLC) and its clinical significance remain unknown. In the present study, the association between B-cell-specific moloney murine leukemia virus insertion site 1 (Bmi1) and miR-203 was investigated. miR-203 was demonstrated to act as a tumor suppressor by regulating the expression of Bmi1. miR-203 expression levels were downregulated in NSCLC tissues while Bmi1 expression was upregulated in NSCLC tissues and cell lines. Furthermore, downregulated Bmi1 or enhanced miR-203 expression inhibited NSCLC cell proliferation and invasion in vitro. In addition, a dual-luciferase reporter assay was performed, which identified Bmi1 as a novel target of miR-203. In conclusion, the present study demonstrated that miR-203 functions as a tumor suppressor and is important in inhibiting the proliferation of NSCLC cells through targeting Bmi1. These findings indicate that miR-203 may be useful as a novel potential therapeutic target for NSCLC.
Introduction
Lung cancer is currently the most common type of cancer worldwide in terms of incidence and mortality, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases (1) . There remains a lack of effective biomarkers or indicators for diagnosis, which often leads to delayed diagnosis and thus the majority of patients with NSCLC present with an advanced stage. Therefore, the development of novel techniques for early diagnosis of NSCLC is required.
MicroRNAs (miRNAs) are a class of small noncoding RNAs that are ~19-24 nucleotides in length, and they regulate ~20-30% of the genes in the human genome (2) . The coding sequences of miRNAs are located in the regions between genes or in the introns (3) . Previous studies have demonstrated that miRNAs are involved in a variety of biological processes, including cell proliferation, differentiation, apoptosis and the development and differentiation of tissues and organs (4, 5) ; and pathological processes, including tumorigenesis and tumor progression (6) . Such regulation is achieved primarily by their partial recombination with the 3'-untranslated region (3'-UTR) of the target mRNA (7, 8) .
A previous study revealed that molecular markers of cancer stem-like cells were connected with malignancies by using gene microarray and sequencing analysis (9) . Another study demonstrated that miRNAs are critical in the carcinogenesis of lung cancer (10) . miR-203 was first identified as a keratinocyte-specific miRNA in the skin, but it is also expressed in the squamous epithelium of the cervix and esophagus (11) . miR-203 regulates embryonic epidermal differentiation and has been implicated in skin diseases, but it also serves as a tumor suppressor or oncogene by regulating proliferation, differentiation, invasion, metastasis and apoptosis in certain types of human cancer (12, 13) . B-cell-specific moloney murine leukemia virus insertion site 1 (Bmi1) is a member of the polycomb repressive complex 1 (PRC1) and is highly expressed in several types of cancer, including lung neoplasm (14, 15) . Yu et al (9) demonstrated that miR-203 inhibited the proliferation of esophageal cancer cells by suppressing Bmi1 directly. However, the level of miR-203 expression and its role in NSCLC remains unclear.
In the present study, the interaction between miR-203 and Bmi1 expression levels was investigated, in addition to the mechanistic role of miR-203 in NSCLC. 5 /well) were seeded into a 24-well plate and co-transfected with 50 ng/well Bmi1-3'-UTR-wild or Bmi1-3'-UTR-mutant vector and 50 nM/well miR-203 mimics (5'-UUG UGC UUG AUC UAA CCA UGU-3') or scrambled microRNA negative control (miR-NC; 5'-UUC UCC GAA CGU GUC ACG UTT-3'). Following culture for 48 h, the LTEP-α-2 cells were collected and the luciferase activities were measured by the Dual-Luciferase Reporter Assay kit (Promega Corporation) on a TD20/20 Luminometer (Turner Designs, Westport, MA, USA). Each experiment was performed in triplicate. The results were expressed as relative Renilla luciferase activities, which were obtained following normalization to firefly luciferase activities. All the transient transfections were performed using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA).
Materials and methods

Patient
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The total RNA from cell lines and NSCLC tissues was extracted using TRIzol reagent (Invitrogen Life Technologies) and measured on a NanoDrop (ND-2000 spectrophotometer; Thermo Fisher Scientific, Inc., Wilmington, DE, USA ) according to the manufacturer's protocol. The synthesis of cDNA was performed using an M-MLV First Strand kit (Invitrogen Life Technologies). The RT primers for mature miR-203 and U6 were designed as RT stem-loop primers (Table I) . Quantitative PCR (qPCR) was performed using a SYBR Green PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) and an ABI7500 Real-Time system (Applied Biosystems Life Technologies, Foster City, CA, USA) were used to quantify the expression levels of RNA. U6 small nuclear RNA (snRNA) and GAPDH mRNA were used as endogenous controls to normalize miR-203 and Bmi1 expression levels. The primer sequences for miR-203, U6, Bmi1 and GAPDH detection are listed in Table I . The relative expression levels were calculated using the ∆∆Ct method.
Western blot analysis. The cells were lysed in RIPA buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) with protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA) at 72 h post-transfection. The total proteins were separated by 10% SDS-PAGE (Sangon Biotech, Co., Ltd., Shanghai, China) and run at a constant voltage of 110 V for 2 h, and subsequently transferred onto polyvinylidene difluoride membranes (Bio-Rad Laboratories, Inc., Hercules, California, USA). The membranes were blocked using 1% bovine serum albumin (Sigma-Aldrich) for 30 min and incubated with the primary antibody Bmi1 (monoclonal, rabbit anti-human; dilution, 1:3000; catalog no. 5856S; Cell Signaling Technology, Danvers, MA, USA) or GAPDH (polyclonal, rabbit anti-human; dilution, 1:5000; catalog no. AP0063; Bioworld Technology, Minneapolis, MN, USA) with agitation overnight at 4˚C. Following 3 washes with Tris-buffered saline and Tween-20 (TBST), the membranes were incubated with secondary antibodies (goat anti-rabbit, dilution, 1:3000; catalog no. sc-2004; Santa Cruz Biotechnology, Dallas, TX, USA) at room temperature for 2 h and then the washes were repeated. The result was visualized using an ECL detection system (Pierce Biotechnology, Inc., Rockford, IL, USA). The Bmi1 protein expression levels were normalized against the GAPDH protein expression levels and the density was quantified using Quantity One software, version 4.6 (Bio-Rad Laboratories, Inc.).
Cell proliferation assay. When the cells were in the logarithmic growth phase, they were seeded into 96-well plates at a density of 5x10 3 cells/well. Cell proliferation was detected using the Cell Counting kit-8 (CCK8) and 5-ethynyl-2'-deoxyuridine (EdU) assays. A CCK8 (Beyotime Institute of Biotechnology, Shanghai, China) was used following the manufacturer's instructions. To estimate the number of viable cells, the optical density at a wavelength of 450 nm (OD450) was measured daily over 4 consecutive days. The EdU assay (Guangzhou RiboBio, Co., Ltd., Guangzhou, China) was used to label cells undergoing DNA replication. At 48 h post-transfection, the cells were cultured with EdU reagent (Guangzhou RiboBio Co., Ltd.) for 2 h to identify those cells in the S-phase of the cell cycle. The EdU medium mixture was then discarded and the cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 30 min at room temperature. Following washes with glycine (2 mg/ml; Sigma-Aldrich) and phosphate-buffered saline for 5 min each, 0.5% Triton X-100 (Sigma-Aldrich) was added to each well. Apollo dyeing reaction buffer (Guangzhou RiboBio, Co., Ltd.) was then added to each well and the plate was shaken in the dark for 30 min at room temperature. The DNA was stained by Hoechst 33342 (Guangzhou RiboBio, Co., Ltd.) dye for 30 min and the proportion of nucleated cells coalescent with EdU were observed using fluorescence microscopy (Olympus IX71; Olympus, Tokyo, Japan).
Apoptosis assay. The cells were collected following 48 h of culture post-transfection with miR-203 and the cell density was adjusted to 1x10 6 cells/ml. The cells were then stained using an Annexin V-FITC Apoptosis Detection kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. The level of apoptosis was assessed by flow cytometry (FC500; Beckman Coulter, Miami, FL, USA).
Transwell invasion assay.
At 24 h post-transfection with miR-203 or miR-NC, the cells were harvested. For the invasion assay, the cells were resuspended in RPMI-1640 medium containing 1% FBS and then seeded at a density of 4x10 4 cells/well into the inserts of the Transwell chamber (Corning Incorporated, Corning, NY, USA), which were coated with Matrigel (27.2 µg/µl; BD Biosciences, Franklin Lakes, NJ, USA). The inserts were subsequently cultured in wells with 20% FBS-containing medium and the plates were incubated at 37˚C for 36 h. Next, the inserts were removed and a cotton tip was used to scrape off the non-invading cells on the upper surface. Cells on the lower surface were then fixed with 4% paraformaldehyde for 30 min at room temperature, and stained with 0.1% crystal violet (Sigma-Aldrich) for a further 30 min. Following fixation, 3 randomly selected images per well were acquired using an inverted microscope (Olympus CKX41; Olympus, Tokyo, Japan) and the average counts were calculated.
Statistical analysis. The results were analyzed using GraphPad Prism Software, version 5.01 (GraphPad Software Inc., La Jolla, CA, USA). All data are presented as the mean ± standard deviation from 3 independent experiments. A 2-tailed Student's t-test was used for the comparison of the mean between groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Upregulation of Bmi1 and downregulation of miR-203 in NSCLC.
To determine whether the expression of Bmi1 was increased in NSCLC, the Bmi1 mRNA expression in 25 paired NSCLC tissues and adjacent non-tumor tissues was quantified by RT-qPCR. This analysis revealed that the mRNA expression level of Bmi1 was significantly increased in NSCLC tissues compared with paired non-tumor tissues (P<0.01; Fig. 1A ). In addition, Bmi1 protein levels were measured in 7 different cell lines. Compared with HBE cells, Bmi1 protein expression levels were significantly increased in the NSCLC cell lines, including the A549, H1650, H226, H1299, H460 and (Fig. 1B) . However, miR-203 was significantly downregulated in the 13 NSCLC samples compared with paired non-tumor tissues (Fig. 1C) .
Bmi1 is a functional target of miR-203 in NSCLC.
Bmi1 is a functional target of miR-203 in NSCLC. Using TargetScan software, the potential targets of miR-203 including SNAI2, PKCα, Bmi1, PLD2, LASP1 and c-myc were identified. To evaluate whether miR-203 regulates Bmi1 expression, miR-203 mimics were transiently transfected into A549 and LTEP-α-2 cells. The results demonstrated that the overexpression of miR-203 markedly reduced Bmi1 protein expression levels in LTEP-α-2 and A549 cells (P<0.05; Fig. 2A ). In accordance with these findings, it is possible that miR-203 directly targets Bmi1 to inhibit its expression. To investigate this hypothesis, potential targets of miR-203 were identified using TargetScan software (www.targetscan.org) and a highly conserved predicted target site on the 3'UTR of Bmi1 mRNA was identified (Fig. 2B ). This region of the Bmi1 3'UTR, including the predicted miR-203 binding site, was then cloned into the psiCHECK-2 vector (Fig. 2C) . The results of the dual-luciferase assay demonstrated that in LTEP-α-2 cells co-transfected with the Bmi1-3'-UTR-wild vector, miR-203 significantly suppressed the luciferase activity compared with the control group. However, this result was not observed with the Bmi1-3'-UTR-mutant vector. These results indicate 01; Fig. 3A) . In addition, the protein level of Bmi1 was successfully suppressed by Bmi1-siRNA, as demonstrated by western blot analysis (Fig. 3B) . The results of the CCK8 assays demonstrated that ectopic miR-203 expression significantly inhibited LTEP-α-2 cell growth compared with the control group (P<0.01; Fig. 3C ). A similar result was observed following the suppression of Bmi1 expression using Bmi1-siRNA (P<0.05; Fig. 3C ). The EdU incorporation assay also indicated that miR-203 inhibited NSCLC cell proliferation. Ectopic expression of miR-203 significantly reduced EdU incorporation in LTEP-α-2 (P<0.01; Fig. 3D) and A549 (P<0.05; Fig. 3E ) cells, (Fig. 4C) . The quantity of LTEP-α-2 and A549 cells that invaded the filter in the miR-203 transfected group was markedly reduced compared with the control group in the two cell types (P<0.01; Fig. 4D ). Similarly, cell invasion was significantly reduced following transfection of Bmi1-specific siRNA (P<0.01 and P<0.05 in LTEP-α-2 and A549 cells, respectively; Fig. 4D ).
Discussion
MicroRNAs are a class of small noncoding RNAs that serve important functions in the regulation of the biological processes of cells, including differentiation, proliferation and apoptosis (16) . Previous studies have demonstrated that miRNA dysregulation occurs in various types of human cancer and these aberrantly expressed miRNAs are considered to serve pivotal roles in carcinogenesis (17) (18) (19) . Whether miRNAs act as oncogenes or tumor suppressor genes depends on the context. For example, miR-203 behaves as a tumor suppressor and is downregulated in pancreatic, glioma and esophageal cancer, while it is upregulated in epithelial ovarian cancer and acts as an oncogene (9, (20) (21) (22) . The present study demonstrated that miR-203 was downregulated in NSCLC specimens, which is in agreement with a 
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previous study (23) . The inhibitory effect of miR-203 expression on the proliferation and invasion of NSCLC cells that was observed in the present study indicates that miR-203 may be involved in the tumorigenesis of lung cancer. Future studies should aim to investigate whether miR-203 expression affects cell cycle progression and can induce cell apoptosis in NSCLC. A previous study demonstrated that downregulated miR-203 levels were significantly associated with lymph node metastasis in laryngeal squamous cell carcinoma (24) . However, to the best of our knowledge, no studies have yet compared the association between miR-203 and lymph node metastasis in lung cancer. The ability of tumor cells to migrate and invade is associated with their cell adhesion properties (25, 26) . The results of the present study indicate that the restoration of miR-203 expression may serve an important role in the progress of NSCLC treatment through inhibiting cell invasion, though further in vivo studies are required to confirm this.
To understand the mechanisms by which miR-203 suppresses cell proliferation, TargetScan software was used to predict the target genes of miR-203. SNAI2, PKCα, Bmi1, PLD2, LASP1 and c-myc were identified in the present study as potential targets. A proportion of these targets have already been demonstrated to be directly regulated by miRNAs, for example SNAI2 expression is reported to be repressed by miR-203 in prostate cells (27) . SNAI2 is a transcription factor that belongs to the E-box-motif family. It inhibits apoptosis by repressing p53-mediated transcription and promotes epithelial-mesenchymal transition by directly repressing E-cadherin (28, 29) . However, it is not clear whether there is an interaction between miR-203 and Bmi1 in NSCLC. Bmi1, a polycomb gene family member, is expressed in almost all tissues and is upregulated in various types of human cancer indicating that Bmi1 may be involved in tumor progression (14) . A previous study demonstrated that Bmi1 is a direct target of miR-128 in glioma and that it serves an important function in glioma proliferation and self-renewal (30) . Another study demonstrated that Bmi1 was overexpressed in lung cancer (15) , which is in accordance with the results of the present study. The present study also demonstrated Bmi1 protein expression levels were significantly increased in the NSCLC cell lines, A549, H1299, H226, H1650, H460 and LTEP-α-2, compared with healthy HBE cells.
To assess whether miR-203 directly represses Bmi1 expression, western blot analysis and a luciferase assay were performed. These analyses corroborated that miR-203 specifically downregulated endogenous Bmi1 expression at the post-transcriptional level.
There are numerous genes predicted to be targets of miR-203, and Bmi1 was the only one confirmed by the present study. There may be other potential targets of miR-203 that function in the tumorigenesis of lung cancer, such as c-myc, therefore further studies focusing on these novel target genes are required. In addition, the sample size in the present study was small, and further studies from different specimens of NSCLC patients are required to strengthen the findings of the present study.
In conclusion, the present study demonstrated that miR-203 represses Bmi1 protein expression by directly targeting the Bmi1 3'UTR, which may reduce the proliferative and invasive abilities of NSCLC cells. These findings indicate that miR-203 may be a novel target for the diagnosis and therapy of NSCLC.
